0001790671-19-000002.txt : 20191107 0001790671-19-000002.hdr.sgml : 20191107 20191107201340 ACCESSION NUMBER: 0001790671-19-000002 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20191107 FILED AS OF DATE: 20191107 DATE AS OF CHANGE: 20191107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Greenhalgh Ellis Skott CENTRAL INDEX KEY: 0001790671 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39130 FILM NUMBER: 191201843 MAIL ADDRESS: STREET 1: C/O TELA BIO, INC. STREET 2: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TELA Bio, Inc. CENTRAL INDEX KEY: 0001561921 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455320061 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-320-2930 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2019-11-07 0 0001561921 TELA Bio, Inc. TELA 0001790671 Greenhalgh Ellis Skott C/O TELA BIO, INC. 1 GREAT VALLEY PARKWAY, SUITE 24 MALVERN PA 19355 0 1 0 0 Chief Science Officer Series A Preferred Stock Common Stock 2025 D Series B Preferred Stock Common Stock 4887 D Warrant 1.16 2017-01-18 2027-01-18 Series B Preferred Stock 1976 D Employee Stock Option (right to buy) 4.45 2017-03-20 2023-03-20 Common Stock 3797 D Employee Stock Option (right to buy) 4.45 2017-05-01 2023-05-01 Common Stock 1265 D Employee Stock Option (right to buy) 4.45 2017-12-11 2023-12-11 Common Stock 5872 D Employee Stock Option (right to buy) 5.93 2019-07-31 2025-07-23 Common Stock 20879 D Employee Stock Option (right to buy) 5.93 2028-02-28 Common Stock 10417 D Stock Option (right to buy) 13.00 2029-11-07 Common Stock 62778 D Shares of Series A and Series B Preferred Stock (collectively, the "Preferred Stock") have no expiration date and are convertible, at the option of the holder, into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). The shares of Preferred Stock will automatically convert into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment in cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering. Shares of Series A Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate. Shares of Series B Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate. The option vested 25% on February 28, 2019, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer. The option vests 25% on November 7, 2020, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer. /s/ Nora Brennan as attorney-in-fact for Elliot Skott Greenhalgh 2019-11-07 EX-24 2 poagreenhalgh.htm

                                POWER OF ATTORNEY



 Know all by these presents, that the undersigned hereby constitutes

and appoints Nora Brennan and Frank Conway with full power to act singly,

as the undersigned's true and lawful attorney-in-fact, with full power of

substitution, to:



 (1) execute for and on behalf of the undersigned, in the undersigned's

capacity as an officer and/or director and/or beneficial owner of Tela Bio,

Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of

the Securities Exchange Act of 1934, as amended, and the rules thereunder;



 (2) do and perform any and all acts for and on behalf of the

undersigned which may be necessary or desirable to complete and execute any

such Form 3, 4, or 5, complete and execute any amendment or amendments thereto,

and timely file such form with the United States Securities and Exchange

Commission and any stock exchange or similar authority; and



 (3) take any other action of any type whatsoever in connection with

the foregoing which, in the opinion of such attorney-in-fact, may be of benefit

to, in the best interest of, or legally required by, the undersigned, it being

understood that the documents executed by such attorney-in-fact on behalf of

the undersigned pursuant to this Power of Attorney shall be in such form and

shall contain such terms and conditions as such attorney-in-fact may approve

in such attorney-in-fact's discretion.



 The undersigned hereby grants to the attorneys-in-fact full power and

authority to do and perform any and every act and thing whatsoever requisite,

necessary or proper to be done in the exercise of any of the rights and powers

herein granted, as fully to all intents and purposes as the undersigned might

or could do if personally present with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact or such

attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be

done by virtue of this power of attorney and the rights and powers herein

granted.



 This power of attorney shall remain in full force and effect until

revoked by the undersigned in a signed writing delivered to the attorney-in-fact.



 IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney

to be executed as of this 26th day of September, 2019.







     /s/Ellis Skott Greenhalgh

     Name: Ellis Skott Greenhalgh

     Title: Chief Technology Officer